Marilys Corbex: On the Side of the People
FDA Grants Priority Review to RYBREVANT FASPRO After Promising 42% Response in Head and Neck Cancer
OncoDaily Lived Experience Advocacy Hub
Ivonescimab Improves Survival After EGFR-TKI Failure
HER2-Low and HER2-Ultralow: What the Categories Change in Practice
Ruiling Yuan: Honored to be Speaking at the Community Oncology Global Congress 2026
Sultan Stambekov: A 20-Fold Increase in Pediatric Cancer Funding in Kyrgyzstan Thanks to President Japarov
Artificial Intelligence in Cancer Immunotherapy
